[Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].
The combined effect of cisplatin (CDDP) with various types of antitumor drugs was examined in P 388 leukemia in vivo. Three representative drugs were chosen from every group of alkylating agents, antitumor antibiotics, antimetabolites, and plant originated drugs. According to their dependency on administration schedules, the dose-dependent and time-dependent drugs were administered once, and daily 5 times, respectively, before and after the single administration of CDDP. In addition to these sequential combinations, simultaneous treatment with CDDP was examined for the drugs which were singly administered. The combined effect was assessed by comparing ILS (increase in life span) in a combined group with the sum of ILS's of each of the 2 single-treatment groups. Synergistic effect was observed in the combination of CDDP with all drugs except MMC. Among them CYC, CQ, ACNU, ADR, PEP, ET, VCR, and VDS produced synergistic effect in any treatment schedules, irrespective of the combination sequences. In the cases of the combination with antimetabolites, the combined effect was depended on the treatment sequences; prior treatment of 5-FU, and posterior treatment of Ara-C and MTX to CDDP administration exhibited a synergistic effect, but the combination in reverse sequence remained almost additive.
Uchida
T
T
Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
Nishikawa
K
K
Shibasaki
C
C
Okamoto
K
K
Arakawa
M
M
Ekimoto
H
H
Takahashi
K
K
D000477:Alkylating Agents / Q000008:administration & dosage; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005260:Female; D007941:Leukemia P388 / Q000188:drug therapy* / Q000401:mortality; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D008811:Mice, Inbred DBA
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D002945:Cisplatin